OUR PUBLICATIONS ON DENDRITIC CELL THERAPY

Hepatocellular carcinoma responds to dendritic cell therapy - case study on 14 patients treated from year 2005-2008                                                       (Poster 47)

Jamal A. Khan and Sharmin Yaqin

Abstract: Dendritic cells (dc) are the master immune cells eliciting both arms of immunity. T cells are almost totally dependent on dc for their maturation. Naive t cells are transformed into committed t lymphocytes with the brief exposure of dc, and during this interaction the specific epitopic representation is guaranteed to pass to t cells. Hepatocellular carcinoma (HCC) is fairly resistant cancer not responding to chemotherapy or mabs. Life span and quality of life get hampered. We have treated 14 patients of HCC from the year 2005 to 2008. 7 patients responded to therapy with decrease of alfafetoprotein to half. These patients have survived on an average of 23 months with 2 patients living for 36 months. Dendritic cell therapy seems to be good option for HCC patients and a large trial is warranted.

Presented in 'Cancer Immunology and Immunotherapy: Building on Success' conference held in National Institute of Health, Bethesda, MD, USA on September 22-23, 2011.

List of Trials held on dendritic cells in different institutions world over

You can click the link above to download the list of trials done on dendritic cell therapy and immunotherapy and read about its efficacy.

Please note: This therapy is customized or tailor-made and therefore cannot be propagated as a pharmaceutical product. However, due to simple blood collection method, where patient's presence is not required; we are able to deliver the product Denvax to patients situated in all corners of India and even to Malaysia.